Bromethenmadinone acetate
Подписчиков: 0, рейтинг: 0
| Clinical data | |
|---|---|
| Other names | BMMA; Bromsuperlutin; 6-Bromo-16-methylene-17α-hydroxy-Δ6-progesterone acetate; 6-Bromo-16-methylene-17α-acetoxypregna-4,6-diene-3,20-dione |
| Drug class | Progestogen; Progestin; Progestogen ester |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C24H29BrO4 |
| Molar mass | 461.396 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Bromethenmadinone acetate (BMMA, also known as bromsuperlutin) is a progestin medication which was developed in Czechoslovakia and was described in 1970 but was never marketed.Analogues of BMMA include chlormethenmadinone acetate, melengestrol acetate, and methenmadinone acetate.
See also
- List of progestogen esters § Esters of 17α-hydroxyprogesterone derivatives
- 16-Methylene-17α-hydroxyprogesterone acetate